Evidence map›Paper›PMID 40357746›Full record

ArticleInflammatory bowel diseases2025

Decreased Fecal Nicotinamide and Increased Bacterial Nicotinamidase Gene Expression in Ulcerative Colitis Patients.

Keiya Aoyama, Ryodai Yamamura, Takehiko Katsurada, Tomohiro Shimizu, Daisuke Takahashi, Eiji Kondo, Norimasa Iwasaki, Akiko Tamakoshi, Tomoyoshi Soga, Shinji Fukuda and 2 more

Abstract read
In one paragraph

Article in Inflammatory bowel diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Keiya AoyamaDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.ORCID 0009-0003-3358-425X
Ryodai YamamuraDivision of Biomedical Oncology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.ORCID 0000-0002-9342-7702
Takehiko KatsuradaDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
Tomohiro ShimizuDepartment of Orthopaedic Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.ORCID 0000-0001-6760-3066
Daisuke TakahashiDepartment of Orthopaedic Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
Eiji KondoCenter for Sports Medicine, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
Norimasa IwasakiDepartment of Orthopaedic Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
Akiko TamakoshiDepartment of Public Health, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
Tomoyoshi SogaInstitute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan.ORCID 0000-0001-9502-2509
Shinji FukudaInstitute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan.
Masahiro SonoshitaDivision of Biomedical Oncology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.ORCID 0000-0003-2890-336X
Naoya SakamotoDepartment of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.

Funding

AMED-CREST JP23gm1010009COI Next Generation Researchers Collaborative Research Fund H30W08JSPS KAKENHI 22H03541JST ERATO JPMJER1902
6 · The paper itself

Abstract

BACKGROUND/

objectiveUlcerative colitis (UC) is significantly linked with gut microbiota, which is essential for maintaining gut health. Their metabolites mitigate gut inflammation and bolster barrier function. Among these metabolites, we focused on vitamin B3, which has been reported to improve the pathogenesis of UC in mice. This study aimed to compare fecal vitamin B3 and gut microbiota between non-UC and UC patients.

methodsWe assessed fecal metabolites and gut microbiota in 71 UC patients (UC group) and 72 non-UC patients (non-UC group) matched by sex and age in 10-year intervals. Fecal samples were collected and metabolites were analyzed using capillary electrophoresis time-of-flight mass spectrometry. Bacterial DNA was extracted for 16S rRNA gene sequencing. We analyzed fecal nicotinamide levels and gut microbiota composition, employing statistical adjustments for confounding factors.

resultsWe found that the UC group exhibited significantly lower fecal nicotinamide levels and α-diversity (Shannon index) compared to the non-UC group. The relative abundance of bacterial genera such as Treponema, UCG-002, and Fusicatenibacter was decreased, while Sellimonas, Fournierella, and Oscillospira were increased in the UC group. Moreover, a negative correlation was observed between Sellimonas abundance and fecal nicotinamide levels in the UC group. Additionally, the UC group showed higher expression of a bacterial gene encoding nicotinamidase compared to the non-UC group.

conclusionsThese findings suggest that gut microbiota dysbiosis contributes to reduced vitamin B3 metabolism in UC patients. The study highlights the potential of replenishing vitamin B3 metabolic pathways as a novel therapeutic approach for UC treatment.

Indexed as

BacteriaColitis, UlcerativeFecesGastrointestinal MicrobiomeNiacinamideAdultCase-Control StudiesFemaleHumansMaleMiddle AgedRNA, Ribosomal, 16SYoung AdultNiacinamideRNA, Ribosomal, 16Sgut microbiotainflammatory bowel diseasenicotinamideulcerative colitisvitamin B3

Identifiers

PMID40357746
PMCPMC12558572

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.